Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Astellas Pharma Inc (OP: ALPMF ) 10.55 UNCHANGED Last Price Updated: 9:30 AM EDT, Jul 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 10.55 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 10.55 Today's Range 10.55 - 10.55 52wk Range 9.170 - 15.80 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval May 17, 2024 Bayer to present detailed Phase 3 OASIS 1 and 2 study results showing elinzanetant significantly reduces moderate to severe menopausal vasomotor symptoms compared to placebo. Via Benzinga Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study October 05, 2023 Merck & Co Inc (NYSE: MRK) announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda met one of its dual primary endpoints of disease-free survival for the adjuvant... Via Benzinga Performance YTD -11.73% -11.73% 1 Month +11.88% +11.88% 3 Month +7.20% +7.20% 6 Month -7.46% -7.46% 1 Year -29.94% -29.94% More News Read More Why Is Seagen Stock Trading Higher Today? September 22, 2023 Via Benzinga What's Going On With Neurology Focused Taysha Gene Therapies Stock Today? September 20, 2023 Via Benzinga Why Shares of Adaptive Biotechnologies Jumped This Week June 16, 2023 Via The Motley Fool Astellas' Menopause Drug Under FDA Review August 18, 2022 Via Benzinga Seagen's Bladder Cancer Trial Data Meets Expectation, Analysts Say July 26, 2022 Via Benzinga Astellas Pharma Licenses Promising Gene Therapy KT430 from Kate Therapeutics Amidst Clinical Hurdles June 08, 2023 Via Benzinga Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition? June 01, 2023 Via TheNewswire.com Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition? June 01, 2023 Via News Direct Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition? May 30, 2023 Via Benzinga Google Launches Tools To Detect Fake Images, Apple May Encounter Delays In iPhone 15 Production, Shake Shack Sees Activist Investor Proxy Fight: Today's Top Stories May 15, 2023 Via Benzinga Astellas' Menopause Drug Sores FDA Approval, After Regulatory Setback May 15, 2023 Via Benzinga Pfizer, Astellas' Xtandi Combo Therapy Cuts Risk Of Metastasis, Death In Prostate Cancer By 58% May 01, 2023 Via Benzinga Astellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration' May 01, 2023 Via Benzinga FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer April 04, 2023 Via Benzinga AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma Partners March 28, 2023 Via Benzinga Japanese Government Urges China To Release Astellas Pharma's Employee March 27, 2023 Via Benzinga Pfizer, Astellas Tout Positive Xtandi Data To Potentially Expand Label For The Prostate Cancer Drug March 17, 2023 Via Benzinga Analyst Says Selecta Biosciences' Gout Candidate Can Potentially Raise The Bar On Several Fronts January 31, 2023 Via Benzinga Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering January 24, 2023 Via Benzinga Astellas Pharma Invests $50M To Support Taysha's Gene Therapy Programs October 25, 2022 Via Benzinga Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate July 26, 2022 Via Benzinga Seagen Shares Jump On Positive Data From Urothelial Cancer Trial July 26, 2022 Via Benzinga The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives June 28, 2022 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.